Wednesday, 20 February 2019
Latest news
Main » (OMER) PT at $26.43

(OMER) PT at $26.43

16 April 2018

Deere & Co now has $48.56 billion valuation. The stock decreased 0.52% or $0.24 during the last trading session, reaching $45.67.

Analysts expect Omeros Corporation (NASDAQ:OMER) to report $-0.34 EPS on May, 9.They anticipate $0.10 EPS change or 41.67% from last quarter's $-0.24 EPS. After $-0.25 actual EPS reported by Omeros Corporation for the previous quarter, Wall Street now forecasts 36.00 % negative EPS growth. 1220710 shares traded on hands while it's an average volume stands with 1443.95K shares.

Omeros Corporation (NASDAQ:OMER) announces OMIDRIA (phenylephrine and ketorolac intraocular solution 1% / 0.3%) has been added to the Veterans Administration's VA National Formulary. It has underperformed by 14.94% the S&P500. Fincl Architects invested in 1,000 shs. 41 funds opened positions while 101 raised stakes. 209.89 million shares or 1.63% less from 213.38 million shares in 2017Q3 were reported. Goldman Sachs Grp owns 46,004 shares or 0% of their United States portfolio. Mitchell Mcleod Pugh Williams has 4,385 shares. Victory Management Inc holds 0% or 1,570 shares. Glenmede Trust Na reported 0% in Flowserve Corporation (NYSE:FLS). Hightower Limited Liability Corp reported 18,014 shs or 0% of all its holdings. Dupont Mgmt reported 0.01% in Deere & Company (NYSE:DE). Aqr Mngmt Ltd Llc owns 43,370 shares or 0% of their USA portfolio.

Since October 23, 2017, it had 0 buys, and 11 sales for $70.30 million activity. JACOBSEN MICHAEL A had sold 1,020 shares worth $22,899 on Wednesday, January 3. Shares for $972,253 were sold by Reed Cory J. The company was maintained on Monday, March 5 by H.C. Wainwright. "Buy" rating has 3, "Sell" are 0, while 3 are "Hold". Therefore 50% are positive. The firm earned "Buy" rating on Wednesday, August 2 by Maxim Group. Corporate insiders own 13.60% of the company's stock. On Tuesday, November 28 the firm has "Buy" rating by Wedbush given. Omeros has an average rating of Buy and an average target price of $33.23. As per Monday, August 24, the company rating was maintained by Morgan Stanley. H.C. Wainwright maintained it with "Buy" rating and $3400 target in Friday, March 23 report. The Company's beta coefficient sits at 3.62. The stock has "Neutral" rating by UBS on Friday, July 29. C M Bidwell & Associates Ltd. bought a new position in shares of Omeros in the fourth quarter valued at approximately $106,000. It also reduced Angi Homeservices Inc stake by 200,000 shares and now owns 1.75M shares. Reata Pharmaceuticals Inc was reduced too.

Investors sentiment decreased to 1.3 in Q4 2017. It has change of 1.56, from 2017Q3's 2.86.

Shares of OMER stock traded down $0.84 during midday trading on Friday, reaching $14.18. 25 grew stakes while 31 funds acquired stakes. Commonwealth Retail Bank Of Aus, a Australia-based fund reported 14,612 shares. Savings Bank Of America De invested in 0% or 77,591 shares. Parametric Port Assoc Ltd Limited Liability Company holds 30,876 shs. Wells Fargo & Company MN increased its stake in Omeros by 13.8% during the 3rd quarter. Jpmorgan Chase accumulated 9,815 shares or 0% of the stock. Moreover, Stifel has 0.02% invested in Omeros Corporation (NASDAQ:OMER). Stratos Wealth Ptnrs Ltd stated it has 0% of its portfolio in Flowserve Corporation (NYSE:FLS).

Caprock holds 67,049 shares. Royal Bankshares Of Canada holds 1,200 shares. Washington Natl Bank owns 0.01% invested in Omeros Corporation (NASDAQ:OMER) for 5,143 shs. Manufacturers Life Ins Comm The owns 0% invested in Omeros Corporation (NASDAQ:OMER) for 65,197 shs. First Advsrs L P stated it has 0% of its portfolio in Omeros Corporation (NASDAQ:OMER). Davenport And Ltd Liability Corporation reported 79,400 shares.

Total analysts of 6 have positions in Omeros (NASDAQ:OMER) as follows: 3 rated it a "Buy", 0 with "Sell" and 3 with "Hold". Omeros had 14 analyst reports since November 2, 2017 according to SRatingsIntel. On Thursday, November 2 the rating was downgraded by Cowen & Co to "Market Perform". The firm earned "Hold" rating on Friday, March 2 by Needham. ValuEngine lowered Omeros from a "hold" rating to a "sell" rating in a research report on Wednesday, February 14th. Maxim Group has "Buy" rating and $2300 target. Cantor Fitzgerald downgraded it to "Neutral" rating and $15 target in Thursday, May 11 report.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, March 1st.

A number of other brokerages have also issued reports on OMER.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. Omeros Corp (Call) now has $684.70 million valuation.